SEPAR highlights CASSANDRA, key to activating lung cancer screening in Catalonia and Castilla-La Mancha

SEPAR highlights the CASSANDRA project as the engine for low-dose CT lung cancer screening in Catalonia and Castilla-La Mancha from 2027.

Add DEMÓCRATA to Google

Ask FREN

Published

3 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 16 de noviembre de 2026 · 16 institutos

  • PP31,4 %
  • PSOE27,1 %
  • Vox18,9 %
  • Frente Amplio6,4 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

ELECCIONES 29N

¿Cuál es tu pronóstico? 29N

Reparte los 350 escaños del Congreso como creas que quedarán el 29 de noviembre. Puedes cambiar tu pronóstico hasta que cierren los colegios.

0 de 350 escaños

PP
PSOE
Vox
Frente Amplio
ERC
Junts
EH Bildu
PNV
Más partidos
Podemos
BNG
SALF
CC
UPN
Adelante
Aliança
Otros

Protegido por reCAPTCHA de Google: privacidad y condiciones

Pronóstico de DemócrataParticipación abierta, no es una encuesta

Dr. Juan Carlos Trujillo, a member of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) and co-coordinator of the project "CASSANDRA", has highlighted the role of this initiative in driving lung cancer screening in Spain, a task which, as he has indicated, "is starting to translate into concrete decisions by the Public Administrations". In this context, he has recalled that Catalonia and Castilla-La Mancha have announced that by 2027 they will have their first screening programs using low-dose computed tomography (CT).

As he explained, the proposal promoted by the scientific society "has helped drive this change in perspective and has demonstrated that it is possible to move toward a model of early detection tailored to our healthcare system", stressing that one is "facing a domino effect". In this line, he stated that "we hope it encourages other autonomous communities to take this step too" in lung cancer screening.

Trujillo has spoken in this way on the occasion of World Lung Cancer Day, which is commemorated on November 17, a date that he has taken the opportunity to emphasize that "a new stage in the prevention of one of the tumors with the highest mortality" in Spain has been started. In his view, "these announcements represent an important step toward the progressive incorporation of screening into the National Health System (SNS), a strategy supported by scientific evidence".

The specialist has insisted on the need to strengthen early detection, recalling that the report "Cancer figures in Spain 2026", prepared by the Spanish Society of Medical Oncology (SEOM) and the Spanish Network of Cancer Registries (REDECAN), for the first time places lung cancer as the cancer that causes the most deaths among women. In 2024, 6,691 deaths were recorded from this cause, compared with 6,563 associated with breast cancer.

The projections included in this document point to the fact that in 2026 there will be 34,908 new cases of lung cancer diagnosed in Spain, of which 11,829 will correspond to women. In light of these figures, experts emphasize that "one of the main challenges in addressing lung cancer is that, often, it is diagnosed when the disease is already in advanced stages, which limits treatment possibilities with curative intent".

Scientific evidence for screening with low-dose CT

Low-dose CT detection makes it possible to locate tumors in their early stages, when there are more therapeutic options and better survival expectations. This advantage is supported by clinical trials such as the European "NELSON" and the American "National Lung Cancer Screening Trial" (NLST), which have shown that screening reduces mortality in people at high risk.

Specifically, the North American NLST study showed a relative 20 percent reduction in lung cancer mortality compared with screening by chest radiography. In turn, the "NELSON" trial found a 24 percent decrease at 10 years among the men who took part in the screening program, compared with those who were not included.

The coordinator of the Thoracic Oncology area of the SEPAR, Dr. José Sanz, has recalled that "the main problem with lung cancer is that, frequently, it does not produce specific symptoms in its early stages and, when the first clinical manifestations appear, the disease may already be advanced," adding that, "for that reason, identifying people at higher risk and offering them tests for early detection can make an important difference in their prognosis".

In any case, specialists insist that screening should focus on population groups selected according to their risk and be carried out within well-structured care pathways, which ensure both the performance of the tests and follow-up of the findings, and access to the diagnostic examinations and treatments needed. To this end, they advocate for a coordinated national-level strategy that guarantees homogeneous criteria across the entire territory.